Save the Date: June 25, Newron Investor Day: Evenamide for poor responders and patients with treatment-resistant Schizophrenia, a Roadmap to Registration
SAVE THE DATE
June 25, 2024
Evenamide: Roadmap to Registration
Investor Day 2024
Join us for a deep dive into the unmet needs and new concepts for treating poor responders and patients with treatment-resistant schizophrenia with three of the world’s leading experts in the fields of neuroscience and treatment-resistant schizophrenia:
Featured speakers to include:
- Anthony Grace, Ph.D., Distinguished Professor of Neuroscience,
Professor of Psychiatry and Psychology
University of Pittsburgh - John Kane, M.D., Co-Director & Professor, Institute of Behavioral Science,
Feinstein Institutes for Medical Research
Professor of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell - Stephen R. Marder, M.D., Daniel X. Freedman Professor of Psychiatry, Semel Institute of Neuroscience & Human Behavior
Director, Section on Psychosis, UCLA Neuropsychiatric Institute - Ravi Anand, MD, Chief Medical Officer
Newron Pharmaceuticals
Tuesday, June 25, 2024
9-11am ET /3-5pm CET
Convene, 530 Fifth Avenue
between 44th & 45th Street, New York City
For further information, or to register for the event, please contact:
Newron
Stefan Weber – CEO, +39 02 6103 46 26, [email protected]
UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting, +44 20 3727 1000, [email protected]
Switzerland
Valentin Handschin, IRF , +41 43 244 81 54, [email protected]
Germany/Europe
Anne Hennecke / Caroline Bergmann, MC Services, +49 211 52925222, [email protected]
USA
Paul Sagan, LaVoieHealthScience, +1 617 374 8800, Ext. 112, [email protected]
About evenamide
Evenamide, an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs) and is devoid of biological activity at >130 other CNS targets. It normalizes glutamate release induced by aberrant sodium channel activity (veratridine-stimulated), without affecting basal glutamate levels, due to inhibition of VGSCs. Combinations of ineffective doses of evenamide and other APs, including clozapine, were associated with benefit in animal models of psychosis, suggesting synergies in mechanisms that may provide benefit in patients who are poor responders to current APs, including clozapine.
About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia. For more information, please visit: www.newron.com